Form 4: BMY Director Acquires Deferred Share Units

Bristol Myers Squibb Director Theodore R. Samuels II acquired 3,996.367 Deferred Share Units as part of a compensation plan.

Summary

• Theodore R. Samuels II, a Director at Bristol Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction occurred on February 1, 2026, with a price of $55.05 per DSU.
• Following this acquisition, Mr. Samuels beneficially owns a total of 67,882.504 Deferred Share Units.
• These DSUs are part of deferred compensation and include dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Each DSU will convert into one share of common stock upon settlement, which occurs when Mr. Samuels ceases to be a director or at a previously specified future date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While a routine compensation event, the director's continued accumulation of equity-linked units reinforces commitment and alignment with long-term company performance.

Positives

• The acquisition of Deferred Share Units by a director demonstrates continued alignment of management interests with shareholder interests.
• The transaction is part of a structured deferred compensation plan, indicating a stable and expected component of executive remuneration.

Future Outlook

The Deferred Share Units will be converted into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person, indicating a future conversion event.

Industry Context

StockSavvy.ai notes that insider acquisitions, even of deferred compensation units, are generally viewed positively as they signal confidence from company leadership in the future performance of the company. In the pharmaceutical industry, such transactions can reinforce stability, especially for a large, established player like Bristol Myers Squibb.

Comparison to Industry Standards

• The acquisition of deferred share units as part of non-employee director compensation is a common practice across various industries, including pharmaceuticals, aligning director incentives with long-term shareholder value.
• Comparable companies such as Pfizer (PFE) and Merck & Co. (MRK) also utilize equity-based compensation plans for their non-employee directors to foster long-term commitment and alignment.

Stakeholder Impact

• Shareholders: The acquisition of deferred share units by a director aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Deferred Share Units will be converted into common stock upon the reporting person ceasing to be a director or at a future specified date.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of deferred share units by a director as part of a compensation plan. While it signals continued insider alignment, it does not present new information significant enough to alter the fundamental investment thesis for Bristol Myers Squibb, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Bristol Myers Squibb, BMY, Deferred Share Units, Insider Transaction, Director Compensation, SEC Form 4, Equity Acquisition, Pharmaceuticals